Skip to main content
Equibles
SPRY logo

SPRY · ARS Pharmaceuticals, Inc.

Track SPRY — free

Use SPRY with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SPRY

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$5.65 -0.45 (-7.38%) At close · Aug 14
Market Cap
$561.88M
Shares
99.45M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.65 Open$5.10 Day$5.00–5.84 52W close$5.13–14.87 Avg vol 30d2.2M Short int21.5M · 21.6% float · 7.8d Short vol73% Last earningsAug 13, 2026 DataDec 2020–Aug 2026 Filing10-Q · Aug 13

Up next

Next earnings call
Nov 11, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Strong Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −36%
      below
      Price vs 50-day avg −25%
      below
      RSI (14) 38
      neutral
      MACD trend Positive
      52-week position 5%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −19%
      trailing
      6-month return −39%
      trailing
      YTD return −52%
      this year
      Relative strength −52%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $8 › 200d $9 — 200d above 50d
      Institutional flow Distributing
      -0% holders QoQ · +38 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      21.57% of float · ▼ -5.4% MoM · 7.8 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Multi-yr high
      204 holders — near 3-yr high, broad support
      Squeeze score 72
      high risk · 0–100
      Fundamentals
      Poor
      Revenue growth −5%
      Y/Y
      EPS growth −2275%
      Y/Y
      Free cash flow $-171.2M
      Balance sheet $55.1M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 72%
      annualized · 1-yr
      Max drawdown −66%
      past year
      ATR 8.4%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Nov 10, 2025
      steady-state, long-term
      Gross-to-net retention at least 50%
      steady-state
      Gross-to-net retention at least 50%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 3 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −36% Bearish
      Price vs 50-day avg
      −25% Bearish
      RSI (14)
      38 Neutral
      MACD trend
      Positive Bullish
      52-week position
      5% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $8 › 200d $9 — 200d above 50d
      Institutional flow Distributing
      -0% holders QoQ · +38 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      21.57% of float · ▼ -5.4% MoM · 7.8 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Multi-yr high
      204 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $5 Now $6 · 5% Range high $15
      vs 200-day avg -36% vs 50-day avg -25%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Market share among field-targeted accounts 8% the second quarter of 2026 —
      Total U.S. epinephrine market share 5% the second quarter of 2026 —
      Unique prescribers 16,000 the second quarter of 2026 —
      Sales force representatives 148 Q1 2026 —
      Healthcare providers who have prescribed neffy 22,500 to date —
      Repeat prescribers 50% to date —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      SPRY
      ARS Pharmaceuticals, Inc.
      this stock
      		$561.88M -51.5% -5.5% — 21.6%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      204
      % held
      91.4%
      Net QoQ
      -3.5M sh
      Top holder
      RA CAPITAL MANAGEMENT, L.…
      Held Float
      View
      Held by Funds
      Fund positions
      147
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      21.5M
      Days to cover
      7.8d
      Change
      -1.2M sh
      View
      Short Volume
      Short vol %
      73%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      57
      Value
      $441
      As of
      Jul 14, 2026
      View
      Off-Exchange
      Off-exchange %
      37.7%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $84.3M
      Net income (FY)
      $-171.3M
      EPS diluted
      $-1.74
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 13, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $250.0K
      Shares
      25.0K
      Filed
      Jun 12, 2026
      View
      Exempt Offerings
      Offering
      $85.0M
      Filed
      Oct 6, 2020
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      SPRY -8.3% -19.3% -38.7% +10.1% -51.5%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -8.7% -23.7% -52.4% +6.2% -65.4%
      Key facts CIK 1671858 CUSIP 82835W108 13F (30d) 203 filings 199 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)